Why GLP-1s aren't lowering employers' costs

Summary

Podcast Summary: Why GLP-1s Aren't Lowering Employers' Costs

Podcast: The Indicator from Planet Money (NPR)
Date: May 19, 2026
Host: Waylon Wong
Guest: Julie Wernow (Trade Offs), Chris Whaley (Health Economist, Brown University), Nick Miller (GLP-1 patient & Connecticut state employee)

---

Overview

This episode investigates whether new and widely used GLP-1 weight loss drugs (Ozempic, Wegovy, Zepbound, etc.) are actually helping employers save money on healthcare costs. Despite the explosion in GLP-1 prescriptions and their life-changing potential for patients, new research and on-the-ground reporting challenge the idea that offering coverage for these drugs leads to long-term employer savings.

---

Key Discussion Points & Insights

1. The Rise of GLP-1s in the Workplace

• Prevalence: 1 in 8 adults in the U.S. are taking GLP-1 drugs, but the vast majority of employer-sponsored health plans don’t cover them for weight loss—only around 20% do.
• Personal Story: Nick Miller, who works for the state of Connecticut, shares his journey with obesity and how his first dose of Ozempic gave him mental clarity, helping to quiet what he describes as “food noise.”
  • Nick Miller (03:33): “We’re gonna behave, right? Good days. Love you.”

2. Why Employers Cover GLP-1s for Some

• Employer Motivation: Employers like the state of Connecticut cover these drugs for employees, hoping that helping staff manage obesity will result in long-term savings by reducing costly medical events (heart attacks, diabetes, etc.).
• Eligibility Gates: Coverage is only offered after employees commit to weight loss tracking, regular clinician check-ins, and other steps. This targets committed individuals and limits overall coverage.
  • Waylon Wong (05:17): “They want to target people who are committed to losing weight… so it’s a gate.”

3. The Economic Reality: No Magic Savings

• Expert Insight: Chris Whaley, health economist, debunks the belief that improving employee health automatically leads to lower company healthcare costs.
  • Chris Whaley (06:36): “Every study that’s looked at that has shown that’s absolutely not the case.”
  • Chris Whaley (06:48): “There’s among employers, you know, this kind of magic ideal that we can improve patient health. And that’s just going to be this magic wand that cuts employer healthcare spending.”
• Key Reasons for Lack of Savings:
  1. Drug Cost: GLP-1s can cost up to $1,700/month (Goodrx), so covering them is a huge expense (06:06).
  2. Program Management Costs: Gatekeeping programs cost extra money, often requiring outsourcing to management firms.
  3. Timing of Health Benefits: Most health benefits appear years down the line—often after an employee leaves for another job or ages into Medicare.
  4. Healthcare Utilization Persists: Even healthier people still use costly healthcare services (sometimes for new reasons, like sports injuries).
     • Chris Whaley (07:59): “If somebody, you know, is out being healthy and active and twists their knee playing pickleball, I think that’s actually, you know, debt positive.”

4. What Employers Actually Save

• Limiting Costs by Restricting Access: The state of Connecticut saw spending on obesity drugs rise, but less rapidly after introducing a gatekeeping management firm. Most of the “savings” come not from improved health, but simply by tightening rules for who can get the drug.
  • Julie Wernow (08:35): “The savings come from the gate, not from the promise of better health.”

5. The Human Impact—Health Benefits vs. Cost

• Patient Transformation: For Nick, getting GLP-1 coverage has been life-changing—he lost significant weight, feels less isolated, and re-engaged with his family and life.
  • Nick Miller (09:37): “I deserve to go after what I want and to have that chance, you know, I deserve to not live in fear or shame and to experience life in the way that everybody can.”
• Societal and Future Outlook: While employer cost savings aren’t (yet) bearing out, the drugs’ prices could eventually drop, similar to cholesterol medications (statins), leading to wider access and potentially a different cost-benefit picture.
  • Waylon Wong (09:17): “Today, around a third of US adults take these medications. But most are cheap now and the vast majority of health plans cover them.”

---

Notable Quotes & Memorable Moments

• Nick Miller (01:31): “That first dose of Ozempic … within three hours that noise was gone. And all of a sudden my brain had room. Like there was silence.”
• Nick Miller (04:10): “To think of [the shot] as cheating, I think is really a disservice to the science and a disservice to my clinicians and a disservice to me.”
• Chris Whaley (06:36): “Every study that’s looked at that has shown that’s absolutely not the case.”
• Chris Whaley (08:52): “Treating obesity and getting people to live happier, healthier lives is a goal in of itself.”

---

Timestamps for Important Segments

• 00:46: Host and guest introductions
• 01:10: Prevalence and significance of GLP-1 drugs in the US
• 03:33: Nick Miller’s family snapshot and powerful personal impact
• 05:17: How employers gatekeep who receives drug coverage
• 06:36 – 07:59: Health economist explains why cost savings don’t materialize
• 08:21: Nick’s employer’s actual spending experience
• 09:37: Nick’s testimonial on the life-changing effects of GLP-1s

---

Takeaways

• GLP-1s profoundly improve health and quality of life for individuals (“Nick’s story makes a strong case that these GLP-1s can lead to a lot of health benefits”—08:40).
• Despite compelling individual stories, there’s no evidence yet that coverage of GLP-1 drugs saves employers money, mainly due to their high cost, additional program expenses, misaligned timeframes for benefit realization, and continued healthcare usage among healthier employees.
• Any employer savings so far comes mainly from restricting access—not from long-term health improvements.
• The argument for employer coverage is, at present, more ethical than economic: “The honest argument is not. This will pay for itself, right?” (Waylon Wong — 08:58)
• This may change if/when drug prices come down, as happened with statins.

---

Transcript

[Narrator]

Once upon a time, there was a listener who just couldn't get enough of the Indicator from Planet Money.

[Waylon Wong]

Who was it? Rumpelstiltskin?

[Narrator]

This listener tuned in all the time but thought, what if there was more?

[Waylon Wong]

But Rumpelstiltskin would be in luck because the Indicator has a brand new newsletter.

[Narrator]

That's right. We talk about what we think matters in the news that week. We answer your listener questions and talk about all the crazy gags we get up to.

[Waylon Wong]

It comes out Friday mornings. Sign up [e-mail] Indicator Newsletter

[Julie Wernow]

NPR.

[Waylon Wong]

This is the Indicator from Planet Money. I'm Waylon Wong here today with my good chum Julie Wernow. She's a reporter for the health policy podcast Trade Offs. And we used to work together at the Chicago Tribune.

[Julie Wernow]

We sure did, Waylon, back in the age of flip phones.

[Waylon Wong]

Julie, you've been reporting recently on all these weight loss medications, Ozempic, Wegovy, Zepbound.

[Julie Wernow]

Right. The number to remember here, one in eight. That's how many adults are on these drugs in the US Alone. Nick Miller is the perfect example. By the time Nick was in his 40s, he weighed more than 400 pounds. He was constantly thinking about food. Should I eat? Do I deserve to eat something he calls food noise.

[Nick Miller]

That first dose of Ozempic on a Tuesday in April, and within three hours that noise was gone. And all of a sudden my brain had room. Like there was silence.

[Waylon Wong]

Nick was lucky to afford the drug. His employee health benefits covered the medication. Like the majority of working age people, he gets his healthcare coverage through his employer. But here's the the vast majority of employer health plans don't cover GLP1s for weight loss. Only 20% do that.

[Julie Wernow]

20% believe it will be good for their bottom line, that the investment will ultimately pay off with fewer medical claims tied to health issues from obesity. Today on the show, will Nick's employer covering his GLP1 save money in the long run? The answer might surprise you

[Narrator]

on consider this, NPR's afternoon news podcast. We cover everything from politics to the economy to the world. But every story starts with a question. At npr, we stand for your right to be curious, to make sense of the biggest story of the day and what it means for you. Follow Consider this wherever you get your podcasts.

[Waylon Wong]

Julie, tell us about your old friend Nick.

[Julie Wernow]

Nick and I grew up together in Connecticut. I hadn't seen him in more than 20 years. We were drama club geeks in high school.

[Waylon Wong]

Oh, what'd you do, guys and dolls? Did you wear fedoras?

[Julie Wernow]

Please Waylon, we were more serious drama kids than that. We were in the pajama game.

[Waylon Wong]

Okay, Thespians, that is. That is serious.

[Julie Wernow]

For high school, Nick still lives in my hometown, Waterford, Connecticut. He and his husband have five kids. Eight, seven, seven, seven, and six. I dropped by before school. It was full on kid chaos. Somehow Nick got everyone out the door.

[Nick Miller]

We're gonna behave, right? Good days. Love you.

[Julie Wernow]

After everyone left, we sat down to talk. Nick said when he got on his GLP1s, his clinician explained obesity as biology.

[Nick Miller]

She was so warm and so welcoming, and she, you know, was able to break down for me what was happening in my body. She also gave me permission, saying, like, and, Nick, this might be a lifelong choice for you. You know, like, you might continue this for the rest of your life, and that's okay.

[Julie Wernow]

And I was like, oh, that was huge for him. Before this, Nick thought taking a weekly shot was cheating somehow.

[Nick Miller]

From where I was to where I am now. To think of that as cheating, I think is really a disservice to the science and a disservice to my clinicians and a disservice to me.

[Waylon Wong]

And this is where Nick's luck comes in. His employer agrees. He works for the state of Connecticut as a supervisor for its Department of Developmental Services. Sean Scanlon is the guy in charge of Nick's employee health plan.

[Chris Whaley]

I believe that these drugs can be effective for not just people losing weight and managing their diabetes, but. But for treating the conditions that then turn to worse problems that then cost plans like the one I run. More money in the long run.

[Julie Wernow]

Sean said they spent about $80 million on GLP1s last year for employees like Nick.

[Waylon Wong]

It's certainly saving money for Nick. With this coverage, nick pays just $12.50 a month. His employer covers the rest. And they do it in an interesting way. They want to target people who are committed to losing weight. Those people. Nick's employer hired an outside company to set some rules.

[Julie Wernow]

He had to weigh himself, track his food and exercise, get labs, and meet with clinicians. The idea here is to get the drugs to the people most likely to benefit and then limit everyone else. It's medical care, but it's also a gate.

[Waylon Wong]

Nick's fellow workers, who are also getting their GLP1s covered, are losing, on average, up to 40% of their body weight. They're also seeing major reductions in indicators that can lead to strokes, heart attacks, and diabetes.

[Julie Wernow]

It's the employer dream. You cover these medications, people get healthier, and then eventually, maybe the health Plan saves money because people avoid expensive medical problems and claims go down.

[Waylon Wong]

I mean, this is a very appealing story.

[Julie Wernow]

It is intuitive, right? You prevent the heart attack, avoid the bill.

[Waylon Wong]

But this is where your reporting took a turn.

[Julie Wernow]

Ever run into an economist at a party?

[Waylon Wong]

Yes, actually.

[Julie Wernow]

Okay. Well, I never see them at parties because they're no fun at parties, Waylon. Oh, that's how I felt when I invited Chris Whaley to this little GLP1 party we're throwing here. He is a health economist at Brown University. He worked on this big report about these employer GLP1 strategies, and he's got some bad news on health savings.

[Chris Whaley]

Every study that's looked at that has shown that's absolutely not the case.

[Julie Wernow]

Chris says employers have this kind of magical thinking that better health will automatically translate into lower health costs down the road.

[Chris Whaley]

There's among employers, you know, this kind of magic ideal that we can improve patient health. And that's just going to be this magic wand that cuts employer healthcare spending,

[Waylon Wong]

at least for now. The magic wand doesn't work for a few reasons, right?

[Julie Wernow]

Reason one, the drugs themselves are expensive. Cash prices can be up to 1700 bucks a month, according to Goodrx. Employers who cover the bulk of this have to take it out of somewhere, either wages or higher premiums.

[Waylon Wong]

Reason two, these management programs that Nick had to sign onto to qualify for coverage cost money, too. About a third of employers are paying outside firms like Nick's employer has. And that adds to a business's overall health coverage costs.

[Julie Wernow]

Reason three, the biggest health benefits generally show up years later, when an employee may not even be on that same employer's health plan. In fact, by then, they're more likely to be on Medicare.

[Waylon Wong]

And finally, reason four, healthier people still use healthcare. One large study of more than half a million patients found no overall spending drop, even years after people started GLP1s.

[Chris Whaley]

If somebody, you know is out being healthy and active and twists their knee playing pickleball, I think that's actually, you know, debt positive.

[Waylon Wong]

You know, I've always been pickleball curious, but now I'm scared because I don't want to twist my knee.

[Julie Wernow]

I don't blame you, Waylon. I actually know some people have gotten hurt playing pickleball.

[Waylon Wong]

Oh, no.

[Julie Wernow]

Yeah, and it's still a claim for the health plan.

[Waylon Wong]

We should note that Nick's employer has seen some benefit. Spending is still going up, but at roughly half the rate it was before they signed on with an obesity management company. Most of those savings come from limiting the number of people on the medications.

[Julie Wernow]

In other words, the savings come from the gate, not from the promise of better health.

[Waylon Wong]

And that makes for a pretty uncomfortable takeaway. It's clear that Nick's story makes a strong case that these GLP1s can lead to a lot of health benefits. Even economist Chris Whaley agrees.

[Chris Whaley]

Treating obesity and getting people to live happier, healthier lives is a goal in of itself.

[Waylon Wong]

But at least for now, the honest argument is not. This will pay for itself, right?

[Julie Wernow]

Although it's worth mentioning, that might change at some point in the long term, GLP1 prices will go down and that could change the cost benefit analysis. Like take cholesterol medications. They began as a high cost drug too, right?

[Waylon Wong]

Today, around a third of US adults take these medications. But most are cheap now and the vast majority of health plans cover them.

[Julie Wernow]

Either way, for Nick, getting the drugs covered has been a life changer. He now weighs just 243 pounds. He says he's less isolated, more center stage in his life with his kids.

[Nick Miller]

I deserve to go after what I want and to have that chance, you know, I deserve to not live in fear or shame and to experience life in the way that everybody can.

[Waylon Wong]

That may not save his employer money

[Julie Wernow]

right now, no, but it might still be worth paying for.

[Waylon Wong]

Julie Warnow, thank you so much for bringing us this story.

[Julie Wernow]

Thank you for having me.

[Waylon Wong]

You can catch Julie on the Trade Offs podcast, available where you get this podcast or on the pickleball court. This episode was produced by Cooper Katz McKimmon, engineered by Sina Lofredo. It was fact checked by Sierra Juarez. Caitlin Cannon is our editor and the indicator is a production of npr.